Racial, Ethnic Differences Seen in Breast Cancer Treatment Declination
By Elana Gotkine HealthDay Reporter
THURSDAY, May 9, 2024 -- For patients with breast cancer, there are racial and ethnic differences in treatment declination, according to a study published online May 9 in JAMA Network Open.
Jincong Q. Freeman, M.P.H., from the University of Chicago, and colleagues examined trends and racial and ethnic disparities in treatment declination and overall survival using data from patients with breast cancer from 2004 to 2020. Four treatment modalities were assessed: chemotherapy, hormone therapy (HT), radiotherapy, and surgery.
Data were included from 2,837,446 patients. The researchers found that 9.6, 6.1, 5.0, and 0.6 percent of the 1,296,488, 1,635,916, 1,893,339, and 2,590,963 patients declined chemotherapy, radiotherapy, HT, and surgery, respectively. The likelihood of declining surgery was increased for American Indian, Alaska Native, or other patients, Asian or Pacific Islander patients, and Black patients compared with White patients (adjusted odds ratios, 1.47, 1.29, and 2.01, respectively. American Indian, Alaska Native, or other patients and Asian or Pacific Islander patients were more likely to decline chemotherapy (adjusted odds ratios, 1.13 and 1.21, respectively); and Black patients were more likely to decline radiotherapy (adjusted odds ratio, 1.05). The likelihood of declining HT was lower for Asian and Pacific Islander patients, Black patients, and Hispanic patients (adjusted odds ratios, 0.81, 0.86, and 0.66, respectively). Higher mortality was seen for Black versus White patients who declined chemotherapy (adjusted hazard ratio, 1.07), while no overall survival differences were seen for Black and White patients who declined HT or radiotherapy.
"Our findings highlight racial and ethnic disparities in declination of treatment recommendations and overall survival, suggesting the need for equity-focused interventions," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted May 2024
Read this next
Donepezil Not Beneficial for Cognitive Impairment in Breast Cancer Survivors
FRIDAY, May 24, 2024 -- A once-daily dose of donepezil does not improve cognitive function among breast cancer survivors exposed to chemotherapy one to five years earlier...
ASCO: Survivors of Early Breast Cancer Can Successfully Attempt Pregnancy
THURSDAY, May 23, 2024 -- Most survivors of stage 0 to III breast cancer who attempt pregnancy postdiagnosis are able to become pregnant and have a live birth, according to a...
4-Dimensional Model Can Predict Lymph Node Metastases in Breast Cancer
THURSDAY, May 23, 2024 -- A deep learning model using tumor dynamic contrast-enhanced breast magnetic resonance imaging (MRI) has high sensitivity for identifying lymph node...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.